Position in ALKS
as of Mar 31, 2026
· filed May 7, 2026
Position Value
$413,393
-$416,549 QoQ
Shares Held
11,691
-60.6% QoQ
Ownership
0.007%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
5 quarters on record
Common Shares in ALKS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Summit Global Investments holds $9,305,086 across 6 Drug Manufacturers - Specialty & Generic names. ALKS ranks #5 (4.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UTHR |
UNITED THERAPEUTICS Corp
|
5,917 | $3,508,662 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
17,083 | $2,250,514 | |
| 3 | TAK |
Takeda Pharmaceutical Co Ltd
|
116,494 | $2,157,468 | |
| 4 | RDY |
Dr Reddys Laboratories Ltd
|
53,845 | $745,753 | |
| 5 | ALKS |
Alkermes plc.
This page
|
11,691 | $413,393 | |
| 6 | SUPN |
Supernus Pharmaceuticals, Inc.
|
4,436 | $229,296 |
All Filings in ALKS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $413,393 | 11,691 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $829,942 | 29,662 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $598,140 | 19,938 | Shares | Sole | 2025-11-03 | |
| 2024-06-30 | $1,128,072 | 46,808 | Shares | Sole | 2024-07-22 | |
| 2024-03-31 | $1,079,957 | 39,895 | Shares | Sole | 2024-04-29 | |
| No filing history on record for this holder in this stock. | ||||||